Women’s Health FAQs

Why Am I Hearing About a New Study on Essure When It’s No Longer In Use?

Publication Date: July 20, 2020

By: Evita Almassi

Essure (a permanent non-hormonal, non-surgical birth control method) is no longer available in the U.S. – but many women still have the device in place, and a study of the device, mandated by the FDA is ongoing.


I heard there’s a new study about the Essure birth control device. I thought it was no longer being used. What’s up?


You’re right. Essure is no longer available in the U.S. – but many women still have the device in place, and a study of the device, mandated by the Food and Drug Administration (FDA), is still ongoing—first, a little background. Essure is a permanent, non-hormonal, non-surgical birth control method designed to be an alternative to tubal ligation. The device consists of two pieces of coiled metal that are inserted into the fallopian tubes through the cervix. Once implanted, scar tissue grows around the coils and eventually, this tissue permanently blocks the fallopian tubes, which prevents sperm from connecting with an egg and ultimately prevents pregnancy. 

Essure was approved by the FDA in 2002. In fact, the NWHN testified at an FDA panel meeting, supporting its approval to give women an alternative to surgical sterilization. But, in our testimony, we also cautioned that extensive follow-up studies were needed to determine exactly how effective it is, and whether its use creates any unexpected risks. The FDA agreed and required the manufacturer to follow clinical trial participants for five years, among other conditions. Sadly, the company’s follow-up wasn’t adequate, and no useful results were reported, leaving women in the dark about what to expect.

A grassroots movement of women who believed that Essure had harmed them eventually forced the FDA to re-consider the device’s safety and effectiveness. Thousands of Essure users described experiencing serious problems, including pelvic pain, autoimmune and neurological disorders, and even uterine rupture. In response, in 2016, the FDA required the device manufacturer to undertake a long-term study comparing the experience of women who received Essure with that of women who chose to be sterilized through surgery. 

Bayer, Essure’s manufacturer, began the study as required but stopped distributing the Essure device in December 2018, after facing mounting pressure from lawsuits, proposed legislation, and the continued activism of women who were unhappy with their device.  

On July 6, 2020, almost 20 years after its approval, the first interim results of the long-term study were released by the FDA. The results confirmed what women who received Essure had been saying all along: the device is far more likely to cause pelvic pain and bleeding than surgical sterilization. According to the FDA, nearly 20% of the women who received the device either had it removed within the first three years of use or underwent an invasive procedure to treat heavy bleeding (endometrial ablation). The FDA also calculated that twice as many women with Essure implants had pelvic pain compared to women who underwent surgical sterilization (9% vs. 4.5%, respectively). Early data indicate that reports of autoimmune conditions are also more common in women using Essure, although those reports have not yet been fully analyzed. 

The FDA-mandated study confirms the critical importance of doctors respecting women’s knowledge of their own bodies. Thousands of women – many of whom were treated dismissively by their doctors – experienced chronic and severe pain after receiving the implant. We hope that the study’s interim results will help women get respectful and appropriate treatment from their doctors if they experience Essure-related complications.   


The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only.

Evita Almassi, MSW, served as the Communications and Digital Marketing Manager for the NWHN. Her 10+ years in nonprofit communications – especially with social media advocacy campaigns – enabled the NWHN to reach and empower more women in their health education and advocacy journeys.

The continued availability of external resources is outside of the NWHN’s control. If the link you are looking for is broken, contact us at [email protected] to request more current citation information.

Get Involved

New ways to empower health care consumers across the nation.